Menu
GWAS Study

High incidence and geographic distribution of cleft palate in Finland are associated with the IRF6 gene.

Rahimov F, Nieminen P, Kumari P et al.

39500877 PubMed ID
GWAS Study Type
708171 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

RF
Rahimov F
NP
Nieminen P
KP
Kumari P
JE
Juuri E
NT
Nikopensius T
PK
Paraiso K
GJ
German J
KA
Karvanen A
KM
Kals M
EA
Elnahas AG
KJ
Karjalainen J
KM
Kurki M
PA
Palotie A
HA
Heliövaara A
ET
Esko T
JS
Jukarainen S
PP
Palta P
GA
Ganna A
PA
Patni AP
MD
Mar D
BK
Bomsztyk K
MJ
Mathieu J
RH
Ruohola-Baker H
VA
Visel A
FW
Fakhouri WD
SB
Schutte BC
CR
Cornell RA
RD
Rice DP
Chapter II

Abstract

Summary of the research findings

In Finland, the frequency of isolated cleft palate (CP) is higher than that of isolated cleft lip with or without cleft palate (CL/P). This trend contrasts to that in other European countries but its genetic underpinnings are unknown. We conducted a genome-wide association study in the Finnish population and identified rs570516915, a single nucleotide polymorphism highly enriched in Finns, as strongly associated with CP (P = 5.25 × 10-34, OR = 8.65, 95% CI 6.11-12.25), but not with CL/P (P = 7.2 × 10-5), with genome-wide significance. The risk allele frequency of rs570516915 parallels the regional variation of CP prevalence in Finland, and the association was replicated in independent cohorts of CP cases from Finland (P = 8.82 × 10-28) and Estonia (P = 1.25 × 10-5). The risk allele of rs570516915 alters a conserved binding site for the transcription factor IRF6 within an enhancer (MCS-9.7) upstream of the IRF6 gene and diminishes the enhancer activity. Oral epithelial cells derived from CRISPR-Cas9 edited induced pluripotent stem cells demonstrate that the CP-associated allele of rs570516915 concomitantly decreases the binding of IRF6 and the expression level of IRF6, suggesting impaired IRF6 autoregulation as a molecular mechanism underlying the risk for CP.

228 Finnish (founder/genetic isolate) cases, 308,799 Finnish (founder/genetic isolate) controls

Chapter III

Study Statistics

Key metrics and study information

708171
Total Participants
GWAS
Study Type
Yes
Replicated
165 Finnish (founder/genetic isolate) cases, 199,935 Finnish (founder/genetic isolate) controls, 71 Estonian (founder/genetic isolate) cases, 198,973 Estonian (founder/genetic isolate) controls
Replication Participants
European
Ancestry
Finland, Estonia
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.